Navigation Links
PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
Date:9/1/2010

tained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reportlinker Adds Advances in Biopharmaceutical Technology in China
2. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
3. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
4. Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life
5. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
6. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
7. Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
8. IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions
9. PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
10. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
11. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of ... than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More ... Headquartered in Dallas, TX , ISN has additional offices ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... , , , ... FOLD ) will announce second quarter 2009 financial results after the ... announcement will be followed by a live conference call and webcast ... Interested participants and investors may access the conference call at ...
... , ... Change at ... constant on a constant, ... 2009 basis rates H1 2009 basis rates, ...
... , ... in Cardiac Core Lab Industry , ... Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced ... of 45 million cardiac cycles for agency facing studies in a single month utilizing the ...
Cached Biology Technology:Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date 2Sanofi-aventis Announces Second Quarter 2009 Results 2Sanofi-aventis Announces Second Quarter 2009 Results 3Sanofi-aventis Announces Second Quarter 2009 Results 4Sanofi-aventis Announces Second Quarter 2009 Results 5Sanofi-aventis Announces Second Quarter 2009 Results 6Sanofi-aventis Announces Second Quarter 2009 Results 7Sanofi-aventis Announces Second Quarter 2009 Results 8Sanofi-aventis Announces Second Quarter 2009 Results 9Sanofi-aventis Announces Second Quarter 2009 Results 10Sanofi-aventis Announces Second Quarter 2009 Results 11Sanofi-aventis Announces Second Quarter 2009 Results 12Sanofi-aventis Announces Second Quarter 2009 Results 13Sanofi-aventis Announces Second Quarter 2009 Results 14Sanofi-aventis Announces Second Quarter 2009 Results 15Sanofi-aventis Announces Second Quarter 2009 Results 16Sanofi-aventis Announces Second Quarter 2009 Results 17Sanofi-aventis Announces Second Quarter 2009 Results 18Sanofi-aventis Announces Second Quarter 2009 Results 19Sanofi-aventis Announces Second Quarter 2009 Results 20Sanofi-aventis Announces Second Quarter 2009 Results 21Sanofi-aventis Announces Second Quarter 2009 Results 22Sanofi-aventis Announces Second Quarter 2009 Results 23Sanofi-aventis Announces Second Quarter 2009 Results 24Sanofi-aventis Announces Second Quarter 2009 Results 25Sanofi-aventis Announces Second Quarter 2009 Results 26Sanofi-aventis Announces Second Quarter 2009 Results 27iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies 2
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... Apricots are important to Turkey, the country where more ... the world. Looking to unlock the mystery of apricots, ... genetic relationship between apricot varieties. New research from a ... genetic link between Turkish and Hungarian apricot cultivars, yielding ...
... a recent issue of HortTechnology , Purdue University researchers ... study of the effects of a technique called "bulb dipping" ... applied as sprays or media drenches, bulb crops can be ... were designed to determine if dipping Easter lily bulbs in ...
... the XXI century. Recent data point to more than a ... 300 million are clinically obese. What is more, the rates ... 155 million children and adolescents being overweight, of which 40 ... what point corporal morphology was influenced by genetics, on the ...
Cached Biology News:Genetic relationship between Hungarian and Turkish apricots confirmed 2Bulb dipping controls Easter lily growth 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
CMRL Medium-1066 (1X) liquid...
... 11(R)-HETE is biosynthesized by the ... purpuratus, and the fresh water hydra, ... 11(R)-HETE relates to oocyte maturation and ... species.11(R)-HETE is also produced when aspirin-treated ...
... (PEBP) does not share significant homology ... PEBP is expressed in the central ... and stomach. One important role ... inhibitory activity against several serine proteases ...
Biology Products: